Remove tag
article thumbnail

Moderna now in the crosshairs of Sens. Warren, Welch over price tag for COVID vaccine

Fierce Pharma

Warren, Welch over price tag for COVID vaccine kdunleavy Wed, 01/25/2023 - 13:16 Moderna now in the crosshairs of Sens.

306
306
article thumbnail

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. Sporting a $3.5M Wed, 11/23/2022 - 10:10.

FDA 287
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim

Fierce Pharma

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim. fkansteiner. Fri, 11/18/2022 - 11:01.

Marketing 229
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

With a lot of money pouring in from MS drugs, their CEO decided that they needed to act like big pharma and moved the company to downtown Cambridge under the guise that it was necessary to get closer to biomedical R&D. If the drug is approved you can bet that it’s going to carry a huge price tag.

article thumbnail

Japan's Ono pays $2.4B for Qinlock-maker Deciphera as biotech readies another approval run

Fierce Pharma

The price tag includes both the approved cancer drug Qinlock and another Deciphera candidate heading to the FDA’s desk in the coming months.

321
321
article thumbnail

Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug in the US

Fierce Pharma

After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S.,

FDA 261
article thumbnail

After filing hitch, Eisai and Biogen begin rolling FDA submission for subcutaneous Leqembi

Fierce Pharma

Late Tuesday, Biogen and Eisai said they kicked off a rolling FDA submission for the subcutaneous version of Leqembi—which is currently infused—after winning a fast track tag from the agency. After suffering a setback with U.S.

FDA 223